NVAX - Novavax, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.61
0.00 (0.00%)
As of 3:45PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.61
Open1.62
Bid1.59 x 800
Ask1.60 x 34100
Day's Range1.57 - 1.64
52 Week Range0.91 - 2.75
Volume2,731,644
Avg. Volume5,544,215
Market Cap614.497M
Beta2.98
PE Ratio (TTM)N/A
EPS (TTM)-0.60
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.93
Trade prices are not sourced from all markets
  • Are These 2 Dark Horse Vaccine Makers Worth the Risk?
    Motley Fool4 days ago

    Are These 2 Dark Horse Vaccine Makers Worth the Risk?

    A new industry report suggests that Novavax and Inovio Pharmaceuticals might be grossly undervalued right now.

  • Why Novavax Sees a Huge Opportunity in Its Influenza Vaccine
    Market Realist5 days ago

    Why Novavax Sees a Huge Opportunity in Its Influenza Vaccine

    Novavax (NVAX) expects the seasonal influenza vaccine market in the world’s top seven markets to grow from ~$3.2 billion in the 2012–2013 season to $5.3 billion by the 2021–2022 season. Influenza is an infectious disease that causes illness in humans, ranging from mild to life-threatening symptoms or death. Largely in part due to infection by unique strains of influenza for which most people have not developed protective antibodies, serious illness occurs in susceptible populations (such as the elderly and very young) as well as the general population.

  • Novavax’s Cash Flow Trends
    Market Realist5 days ago

    Novavax’s Cash Flow Trends

    Novavax (NVAX) completed a public offering of ~34.9 million shares of its common stock in April. Through this offering, the company raised ~$54 million. In the first quarter, Novavax sold 15.7 million of its common shares, raising $32.3 million in net proceeds. Its number of outstanding shares is expected to rise to ~400 million from ~262 million between fiscal 2015 and fiscal 2019.

  • Analyzing Novavax’s Financial Performance
    Market Realist5 days ago

    Analyzing Novavax’s Financial Performance

    Novavax (NVAX) generates revenue in the form of grants from the Bill and Melinda Gates Foundation (or BMGF) for the development of its RSV F (respiratory syncytial virus fusion protein) vaccine for infants via maternal immunization. During the first quarter of fiscal 2018, the company’s revenue rose YoY (year-over-year) to $9.7 million from $5.7 million. The BMGF awarded an $89.1 million grant to Novavax in 2015, of which the company has recognized $51 million so far.

  • How Much Upside Analysts See In Novavax Stock
    Market Realist5 days ago

    How Much Upside Analysts See In Novavax Stock

    Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing recombinant nanoparticle vaccines and adjuvants to market. Of the eight analysts covering Novavax, four have recommended “buy” or a higher rating, three have recommended “hold,” and one has recommended “sell.” Their mean rating for the stock is 2.4, and their target price is $3.93, implying a 144% upside based on its June 13 closing price of $1.61. Of the 20 analysts covering Merck (MRK), 15 have recommended “buy” or a higher rating, and five have recommended “hold.” Their mean rating for the stock is 2, and their target price is $69.02.

  • Analyzing Novavax’s Clinical Vaccine Programs
    Market Realist5 days ago

    Analyzing Novavax’s Clinical Vaccine Programs

    In addition to developing RSV (respiratory syncytial virus) and influenza vaccines, Novavax (NVAX) is also developing immune-stimulating saponin-based adjuvants through its Swedish subsidiary, Novavax AB. Its lead adjuvant, Matrix-M, has been shown to enhance immune response and has been well tolerated in multiple clinical trials.

  • GlobeNewswire7 days ago

    New England Journal of Medicine Publishes Novavax' NanoFlu Clinical Trial Data

    NanoFlu TM  Phase 1/2 trial data published in a peer-reviewed letter to the editor in  The New England Journal of Medicine NanoFlu demonstrates significantly improved immune responses against a panel of ...

  • GlobeNewswire7 days ago

    New England Journal of Medicine Publishes Novavax’ NanoFlu Clinical Trial Data

    NanoFlu TM Phase 1/ 2 trial data published in a peer-reviewed letter to the editor in The New England Journal of Medicine NanoFlu demonstrates significantly improved immune responses against a panel of ...

  • 3 Penny Stocks Poised for Growth the Rest of 2018
    InvestorPlace7 days ago

    3 Penny Stocks Poised for Growth the Rest of 2018

    Many of the so-called “rags to riches” stories coming from the stock market involve penny stocks. Penny stocks usually achieve that status when investor cast legitimate doubts about their financial future. Although the following three stocks pose significant risks, conditions have emerged that could move them beyond penny-stock status and position today’s investors for huge profits.

  • ACCESSWIRE29 days ago

    Free Technical Insights on OPKO Health and Three Other Biotech Stocks

    Stock Research Monitor: NBIX, NVAX, and ONTX LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want a free Stock Review on OPK sign up now at www.wallstequities.com/registration . On Monday, benchmark US ...

  • 3 Top Stocks Under $5
    Motley Foollast month

    3 Top Stocks Under $5

    These low-priced stocks could generate huge returns. But there are huge risks, too.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of NVAX earnings conference call or presentation 9-May-18 8:30pm GMT

    Q1 2018 Novavax Inc Earnings Call

  • Investopedialast month

    Top 3 Healthcare Penny Stocks for 2018

    The healthcare industry can be precarious for stocks of large companies, much less penny stocks. Of course, small-cap healthcare companies can be nudged out of the market by big competitors, and they can simply become unable to service debt when products and services don't sell quickly enough. None of these are new companies – they have made progress in developing products and finding the marketing outlets that are needed to sustain them.

  • Associated Presslast month

    Novavax: 1Q Earnings Snapshot

    On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 14 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • GlobeNewswirelast month

    Novavax Reports First Quarter 2018 Financial Results

    GAITHERSBURG, Md., May 09, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the first quarter ended March 31, 2018. First Quarter and Subsequent Achievements: ...

  • GlobeNewswirelast month

    Novavax Reports First Quarter 2018 Financial Results

    GAITHERSBURG, Md., May 09, 2018-- Novavax, Inc., today announced its financial results for the first quarter ended March 31, 2018.. First Quarter and Subsequent Achievements:. In May 2018, Novavax reached ...

  • GlobeNewswirelast month

    Novavax Reaches Significant Enrollment Milestone in the Prepare(TM) Phase 3 Trial of its RSV F Vaccine

    Novavax, Inc. (NVAX) today announced it has reached a significant milestone in the Prepare(TM) Phase 3 clinical trial of its respiratory syncytial virus F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization. Prepare is a global, pivotal Phase 3 clinical trial of the RSV F Vaccine, in healthy, third trimester pregnant women, which initiated in December 2015. "Reaching this enrollment target for the Prepare trial is a significant milestone in the advancement of our RSV F Vaccine franchise," said Stanley C. Erck, President and CEO of Novavax, Inc. "RSV remains an urgent global unmet medical need due to the mortality and morbidity associated with RSV disease in infants and the absence of a vaccine to prevent such disease.

  • GlobeNewswirelast month

    Novavax Reaches Significant Enrollment Milestone in the Prepare(TM) Phase 3 Trial of its RSV F Vaccine

    Novavax, Inc. (NVAX) today announced it has reached a significant milestone in the Prepare™ Phase 3 clinical trial of its respiratory syncytial virus F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization. Prepare is a global, pivotal Phase 3 clinical trial of the RSV F Vaccine, in healthy, third trimester pregnant women, which initiated in December 2015. “Reaching this enrollment target for the Prepare trial is a significant milestone in the advancement of our RSV F Vaccine franchise,” said Stanley C. Erck, President and CEO of Novavax, Inc. “RSV remains an urgent global unmet medical need due to the mortality and morbidity associated with RSV disease in infants and the absence of a vaccine to prevent such disease.

  • Will Novavax Inc’s (NASDAQ:NVAX) Earnings Grow In The Years Ahead?
    Simply Wall St.last month

    Will Novavax Inc’s (NASDAQ:NVAX) Earnings Grow In The Years Ahead?

    Novavax Inc’s (NASDAQ:NVAX) released its most recent earnings update in December 2017, which indicated that losses became smaller relative to the prrior year’s level – great news for investors TodayRead More...

  • GlobeNewswire2 months ago

    Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 9, 2018

    GAITHERSBURG, Md., May 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2018 financial and operating results following the close of U.S. financial ...

  • GlobeNewswire2 months ago

    Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 9, 2018

    GAITHERSBURG, Md., May 02, 2018-- Novavax, Inc. today announced it will report its first quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, May 9, ...

  • 3 Stocks That Could Put Amazon's Returns to Shame
    Motley Fool2 months ago

    3 Stocks That Could Put Amazon's Returns to Shame

    Investors looking for the next Amazon should consider an e-commerce facilitator, a vaccine developer, and a supplier of autonomous car parts.

  • Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?
    Zacks2 months ago

    Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?

    Is Novavax, Inc. (NVAX) Outperforming Other Medical Stocks This Year?

  • Don't Get Greedy With Novavax, Inc. Stock
    Motley Fool2 months ago

    Don't Get Greedy With Novavax, Inc. Stock

    Novavax's abysmal track record should be a huge red flag for potential shareholders.

  • 3 Biotech Stocks That Will Thrive Amid Market Instability
    InvestorPlace2 months ago

    3 Biotech Stocks That Will Thrive Amid Market Instability

    The U.S. stock market is facing a severe volatility since the last couple of months despite a strong start this year. This downside can mainly be attributable to a potentially damaging trade war between the world’s two largest economies, United States and China, since this February.Source: Shutterstock